Phase 3 results indicate sacituzumab tirumotecan i..

25 w

Phase 3 results indicate sacituzumab tirumotecan improves overall and progression-free survival in advanced endometrial cancer, a potential game changer for patients after standard therapies.

news.spreely.com

Phase 3 Trial Shows Sacituzumab Improves Endometrial Cancer Survival

A new drug called sacituzumab tirumotecan, or sac-TMT, just announced encouraging Phase 3 results for advanced endometrial cancer, and researchers are calling it a potential game changer for patients whose disease progressed after standard therapies. Merck revealed that sac-TMT met its "primary endpoints" of overall survival and progression-free survival in the global TroFuse-005 trial, which...

Beğen

Yorum Yap

Paylaş

25 w

Phase 3 Trial Shows Sacituzumab Improves Endometrial Cancer Survival

Dil